The EMPA–KIDNEY trial assessed the effects of empagliflozin 10 mg once daily in patients with CKD, and included the broadest range of patients at risk of progression of the four reported large SGLT2 inhibitor trials in CKD [6]. The gene discussed is SLC5A2; the disease is chronic kidney disease.